| Literature DB >> 24834429 |
Paolo Pietro Bianchi1, Wanda Petz1, Fabrizio Luca2, Roberto Biffi3, Giuseppe Spinoglio4, Marco Montorsi5.
Abstract
The current standard treatment for rectal cancer is based on a multimodality approach with preoperative radiochemotherapy in advanced cases and complete surgical removal through total mesorectal excision (TME). The most frequent surgical approach is traditional open surgery, as laparoscopic TME requires high technical skill, a long learning curve, and is not widespread, still being confined to centers with great experience in minimally invasive techniques. Nevertheless, in several studies, the laparoscopic approach, when compared to open surgery, has shown some better short-term clinical outcomes and at least comparable oncologic results. Robotic surgery for the treatment of rectal cancer is an emerging technique, which could overcome some of the technical difficulties posed by standard laparoscopy, but evidence from the literature regarding its oncologic safety and clinical outcomes is still lacking. This brief review analyses the current status of minimally invasive surgery for rectal cancer therapy, focusing on oncologic safety and the new robotic approach.Entities:
Keywords: laparoscopic surgery; neoadjuvant therapy; rectal cancer; robotic surgery; total mesorectal excision
Year: 2014 PMID: 24834429 PMCID: PMC4018567 DOI: 10.3389/fonc.2014.00098
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244
Comparison of circumferential resection margin positivity in open and laparoscopic total mesorectal excision (TME).
| Overall (%) | AR (%) | APR (%) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Open | LAP | Open | LAP | Open | LAP | ||||
| CLASICC ( | 14 | 16 | 0.8 | 6 | 12 | 0.19 | 26 | 20 | 1.0 |
| COREAN ( | 4.1 | 2.9 | 0.7 | 3.4 | 2.7 | 1.0 | 8.3 | 5.3 | 1.0 |
| COLOR II ( | 10 | 10 | 0.8 | 22 | 9 | 0.01 | 25 | 8 | 0.003 |
AR, anterior resection; APR, abdominoperineal resection; LAP, laparoscopic resection; .
Oncologic results of laparoscopic and robotic surgery for rectal cancer.
| Harvested lymph nodes ( | Distal resection margin (cm) | Positive CRM (%) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| ROB | LAP | ROB | LAP | ROB | LAP | ||||
| Park et al. ( | 17.3 | 14.2 | 0.06 | 2.1 | 2.3 | ns | 4.9 | 3.7 | 0.5 |
| Kim and Kang ( | 14.7 | 16.6 | ns | 2.7 | 2.6 | 0.09 | 3 | 2 | ns |
| Kwak et al. ( | 20 | 21 | 0.7 | 2.2 | 2.8 | 0.8 | 1.7 | 0 | >0.9 |
| Baek et al. ( | 13 | 16 | 0.07 | 3.6 | 3.8 | 0.6 | 2.4 | 4.9 | 1 |
| Bianchi et al. ( | 18 | 17 | 0.7 | 2 | 2 | 1.0 | 0 | 4 | 0.9 |
| Baik et al. ( | 18.4 | 18.7 | 0.8 | 4 | 3.6 | 0.4 | 7 | 8 | 0.7 |
| Patriti et al. ( | 10.3 | 11.2 | >0.05 | 2.1 | 4.5 | >0.05 | 0 | 0 | ns |
Meta analysis [Memon et al. (.
CRM, circumferential resection margin; ROB, robotic resection; LAP, laparoscopic resection; .
Clinical results of laparoscopic and robotic surgery for rectal cancer.
| Conversions (%) | Hospital stay (days) | Complications (%) | | ||||||
|---|---|---|---|---|---|---|---|---|---|
| ROB | LAP | ROB | LAP | ROB | LAP | ||||
| Park et al. ( | 0 | 0 | 1 | 9.9 | 9.4 | 0.5 | 29.3 | 23.2 | 0.4 |
| Kim and Kang ( | 2 | 3 | 1 | 11.7 | 14.4 | 0.006 | 20 | 27 | 0.4 |
| Kwak et al. ( | 0 | 3.4 | 0.4 | NA | NA | 32 | 27 | ns | |
| Baek et al. ( | 7.3 | 22 | 0.116 | 6.5 | 6.6 | 0.8 | 22 | 27 | 1 |
| Bianchi et al. ( | 0 | 4 | NA | 6.5 | 6 | 0.4 | 16 | 24 | 0.5 |
| Baik et al. ( | 0 | 10.5 | 0.013 | 5.7 | 7.6 | 0.001 | 10.7 | 19.3 | 0.025 |
| Patriti et al. ( | 0 | 19 | <0.05 | 11.9 | 9.6 | >0.05 | 30.6 | 18.9 | >0.05 |
Meta analysis [Memon et al. (.
ROB, robotic resection; LAP, laparoscopic resection; .
Clinical and oncologic outcomes of 50 minimally invasive total mesorectal excision (TME).
| ROB | LAP | ||
|---|---|---|---|
| Complications (%) | 16 | 24 | 0.5 |
| Median (range) operating time (min) | 240 (170–420) | 237 (170–545) | 0.2 |
| Conversions | 0 (0) | 1 (4) | |
| Median (range) first bowel movements (days) | 2 (1–7) | 3 (1–4) | 0.5 |
| Median (range) hospital stay (days) | 6.5 | 6 | 0.4 |
| Median (range) lymph nodes/patient ( | 18 | 17 | 0.7 |
| Median (range) distal resection margin (cm) | 2 | 2 | 1.0 |
| CRM positivity | 0/25 (0) | 1/25 (4) | 0.9 |
Bianchi et al. (.
ROB, robotic resection; LAP, laparoscopic resection; .